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ABSTRACT
Prevention of Chronic Inflammation by Targeting Macrophage Integrin aDb2
by
Cady Forgey

Macrophage integrin aDb2 promotes macrophage retention and accumulation within
inflamed tissue, a key event in development of chronic inflammation. Recently, the P5
peptide was identified as a specific inhibitor for integrin aDb2 interaction with 2-(ωcarboxyethyl) pyrole (CEP), a ligand at inflammatory sites. This thesis aims to identify
integrin aD I-domain amino acids involved in binding P5 peptide and likewise to CEP.
We propose that non-conserved, basic amino acids of the integrin aDb2 I-domain are
responsible for binding to P5 peptide and likewise to CEP. Eight amino acids were
analyzed by generating six mutant aD I-domains: K180[A], R189[Q], K205[L], HHK223225[NIT], K233[A], and K246[A]. Mutagenic constructs were created using PCR sitedirected mutagenesis, then transformed into E.coli BL21 cells for IPTG-induced protein
expression. Of the 6 mutant I-domains analyzed, amino acid K246 was critical in binding
to P5 peptide and CEP through ForteBio Protein-Protein Assay, as well as to CEP by
cell adhesion assay.
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CHAPTER 1. INTRODUCTION
Inflammation is the fundamental mechanism used to defend host cells and repair
host tissues after exposure to invading pathogens, harmful stimuli or physical injury.
The inflammatory response describes a complex cascade of coordinated cellular events
which function to first eliminate factors that interfere with homeostasis, followed by
repairing the damage incurred by the surrounding tissue.1 While inflammation is
intended to be protective, failure to end an inflammatory response is often detrimental to
host health. Unresolved inflammation leads to an accumulation of inflammatory cells,
which over time has very damaging effects on host tissues and serves as the origin of
chronic inflammatory disease. 2,3
Diseases associated with chronic inflammation rank among the most significant
causes of death worldwide and include cardiovascular disease, diabetes, cancer,
arthritis and joint disease, allergies, and chronic respiratory diseases. 4,5 In May of 2017,
the Rand Cooperation published a study which estimated that almost 60% of Americans
live with at least one chronic inflammatory disease with the prevalence expected to
steadily increase over the next 30 years.6 Clearly, gaining a deeper understanding of the
molecular mechanisms behind chronic inflammation and developing new methods to
prevent and treat chronic inflammatory disease is imperative for human health.
A key event in the development of chronic inflammation is the accumulation and
retention of pro-inflammatory macrophages within inflamed tissue. For this reason,
targeting these pro-inflammatory macrophages has become an attractive avenue for
developing new methods to prevent and treat chronic inflammatory reactions.7,8
Expanding on several important findings by Yakubenko and his group, this thesis aims
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to identify the specific amino acids of integrin aDb2 that participate in binding to the novel
P5 peptide and likewise to 2-(ω-carboxyethyl) pyrole, or CEP, a ligand at inflammatory
sites. The introduction begins with a brief explanation of the acute inflammatory
response, followed by a discussion of chronic inflammation, integrins, and previous
findings by Yakubenko, his group, and others which led to the research project.
The Acute Inflammatory Response
Acute inflammation serves as the first-line of defense following exposure to
harmful stimuli or physical injury and is essential for maintaining host vitality.9 An acute
inflammatory response is initiated when pattern recognition receptors (PRRs) on the
surface of resident immune cells recognize pathogen-associated molecular patterns
(PAMPs) or damage-associated molecular patterns (DAMPs) present in the tissue.1
Recognition of a PAMP or DAMP activates a resident immune cell and triggers the
release of chemokines and several other inflammatory mediators. The release of these
molecules alters the surface expression of nearby vascular endothelial cells, induces
vasodilation, and increases blood flow and vascular permeability.10
The First Wave of Inflammation: Neutrophils
When an inflammatory response is initiated, neutrophils are the first major cell
type recruited to the site of inflammation. Changes in blood flow, vessel permeability
and the molecular surface expression of cells lining the vessel wall allow circulating
neutrophils to roll along the endothelium and enter the tissue through extravasation.11 In
the tissue, a chemokine gradient established by local cells and other chemoattractant
molecules guide neutrophils towards the inflammatory site. Once at the site, neutrophils
function in removal of pathogens by generating oxidative bursts, releasing granule
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contents, phagocytosis, and through the formation of NETs.12 Neutrophils have a major
role in modulating the inflammatory response through releasing a variety of important
inflammatory mediators. While neutrophils dominate the first phase of inflammation, we
are now beginning to understand the importance of their roles which extend beyond this
initial phase, including their formation of a close partnership with the macrophage which
heavily influences the entire inflammatory response.13
The Second Wave of Inflammation: Macrophages
Following the infiltration of neutrophils, monocyte-derived macrophages are the
second major cell type to arrive at the site of inflammation. Circulating monocytes leave
the bloodstream and transmigrate into the tissue by extravasation, where they
differentiate into a macrophage.14 Monocyte-derived macrophages are highly plastic
cells of the immune system capable of altering their phenotypic expression based on a
variety of signals and cues from the surrounding microenvironment.15 This dynamic
nature of macrophages allow them to play a major role in directing the inflammatory
response, from phagocytic removal of insult and cell recruitment to later promoting
healing and tissue regeneration during resolution phase of inflammation.
While a wide spectrum of possible phenotypes exist, macrophages are broadly
characterized as M1-like or M2-like based on their mechanism of activation, molecular
expression, and behavioral patterns. M1-like phenotypes are classically activated and
are generally considered pro-inflammatory, while M2-like macrophages are alternatively
activated and are generally considered anti-inflammatory.16 M1-like macrophages are
highly phagocytic and typically function at the inflammatory site to remove the stimulus,
influence the behavior of nearby cells, and clear debris from the site. M1-like
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macrophages stimulate inflammation by promoting recruitment of additional immune
cells to the site and producing pro-inflammatory cytokines, chemokines and other
inflammatory intermediates.17
Resolution of Inflammation
As removal of the inflammatory stimulus is achieved, the macrophage population
is believed to shift from an M1-like phenotype towards expression of an M2-like
phenotype. 18 M2-like macrophages suppress the inflammatory response through
releasing anti-inflammatory mediators, regulating behavior of other cells and promote
healing and tissue regeneration.17 Much remains unknown about these changes in
macrophage phenotype expression, but the switch is highly regulated through many
interconnected signals and pathways. This tight regulation is highly important as this
transition in macrophage phenotype shifts the response from pro-inflammation to
resolution of inflammation, repair and regeneration. Interestingly, neutrophil cell dying is
among several factors shown to play a role in resolution of inflammation by influencing
macrophages to express an M2 phenotype.13 The anti-inflammatory M2-like
macrophages direct the repair process and as the damaged tissue becomes restored,
immune cells leave the site.19 The acute inflammatory response is depicted in Figure
1A.
Chronic Inflammation
By nature, the acute inflammatory response is intended to protect the host and
repair damaged tissue. However, it is crucial that the inflammatory response be tightly
regulated and that the resolution of inflammation is achieved.20 Failure to resolve an
inflammatory response leads to development of chronic inflammation, which contributes
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significantly to the pathogenesis of many prevalent and devastating diseases.21 While
many pathways and cellular processes involved in initiating and maintaining an acute
inflammatory response have become increasingly well-defined, much remains unknown
about resolution of inflammation and the associated molecular pathways involved in
development of chronic inflammation.22 Unlike acute inflammation, chronic inflammation
is a prolonged and maladaptive response which may originate due to underlying
pathophysiology, exposures to certain substances, autoimmune disorders, oxidative
stress, recurrent episodes of acute inflammation and in some cases, without apparent
injury or disease.5 Although there are several potential origins, a common key event in
the development of chronic inflammation is the accumulation and retention of proinflammatory M1-like macrophages at the inflammatory site.
Role of Macrophages in Chronic Inflammation
Chronic inflammation occurs when leukocytes present at the site of inflammation
are by some means unable to remove an inflammatory stimulus. As a result, additional
leukocytes are continually recruited to the area in an attempt to overcome the insult.
Over time, this leads to an accumulation of inflammatory cells, namely pro-inflammatory
macrophages. As pro-inflammatory macrophages attempt to remove the stimulus using
methods that result in collateral cell and tissue damage, their combined efforts have
very damaging effects on the surrounding host tissue.22 Over time, this leads to the
formation of a chronic inflammatory lesion and the eventual development of a chronic
inflammatory disease. 23 A schematic depicting acute and chronic inflammatory
reactions is shown below in Figure 1B.
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Figure 1: Inflammation. From Tabas I, Glass CK. Anti-inflammatory therapy in chronic
disease: challenges and opportunities. Science. 2013;339(6116):166-172. Reprinted
with permission from AAAS. 1A. Progression of acute inflammation in response to a
bacterial infection. Neutrophils are first to infiltrate the infected tissue, followed by the
appearance of inflammatory monocyte-derived macrophages. After the pathogen is
cleared, macrophages direct the immune response to resolution and repair stage until
parenchyma is achieved. 1B. Chronic inflammatory reactions occur when immune cells
are unable to eradicate stimuli provoking an inflammatory response. The inflammatory
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response is amplified due to the persistent presence of stimulus and resolution of
inflammation is not achieved, resulting in host tissue damage.

As pro-inflammatory macrophages are the predominant cell population within
these lesions and are also responsible for much of the damage sustained by chronic
inflammatory reactions, inhibiting their ability to migrate and adhere to the site is an
attractive method for prevention and treatment of chronic inflammatory reactions. During
inflammation, the migration and adherence of monocytes and macrophages is largely
mediated by the b2 integrins, an important subfamily of cell adhesion receptors which
belong to the integrin family.
The Integrin Family
Discovered in the late 1980’s by Richard O. Hynes, the integrins are a large
family of heterodimeric, glycoprotein adhesion receptors which span the cell membrane
of virtually all nucleated metazoan cells. 24, 25 Collectively, the integrins carry out a
variety of essential functions by allowing the cell to sense and respond to a dynamic
extracellular environment. Serving as a physical link between the cell and its
surroundings, integrins have direct roles in development, cell adhesion, cell migration,
and cell-cell interactions.26 Further, integrins are an integral part of several signal
transduction pathways within the cell including those involved cell survival,
transcriptional control, cell proliferation, cell motility, and organization of the internal
cytoskeleton.27 Currently, there are 24 members belonging to this essential family of
adhesion receptors.
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Integrin Structure
Integrins are constructed from one α and one β subunit held together by noncovalent interactions.28 Consisting of a large globular head and two leg regions that
insert into the plasma membrane, each integrin contains a large extracellular domain, a
transmembrane domain, and a short cytoplasmic tail. The α subunit forms one of the leg
structures while the β subunit comprises the other. The large globular head is formed
from the association of the α and β subunits and contains the sites for ligand binding. In
vertebrates, 24 integrin heterodimers are assembled from 18 different α subunits and 8
different β subunits.29 While the alpha and beta subunits do not show homology to each
other, there are conserved regions and areas of homology within the group of alpha
subunits and beta subunits themselves.27 Each integrin heterodimer has a unique
function and ligand-binding properties based upon their different individual subunit
compositions. The 24 heterodimers of the integrin family are shown below in Figure 2.

Figure 2: The Integrin Family. From Barczyk M., Carracedo S. & Gullberg D. Integrins.
Cell Tissue Res. 2010; 339(269). Reprinted with permission from Elsevier. There are 24
heterodimers comprising the human family of integrins, each formed by the association
of an α and b subunit.
17

α subunit. Generally, the α subunits are largely responsible for the ligandspecificity of each integrin. The extracellular portion of each α subunit is composed of 4
domains: a thigh, a calf-1 domain, a calf-2 domain, and the seven-bladed b-propeller.30
Together, the thigh, the calf-1 domain, and the calf-2 domain form a leg structure that
supports the seven-bladed B-propeller of the integrin head. Of the 18 α subunits
discovered thus far, 9 contain an additional I-domain which is inserted in-between blade
2 and blade 3 of the b-propeller.31 The N-terminal I-domain consists of approximately
180 amino acids and is composed of 5 β-sheets surrounded by 7 α-helices.31 The Idomain is critical to ligand binding for integrins possessing this domain as it contains the
metal ion-dependent adhesion site, or MIDAS. Located on the top face of the α subunit
I-domain, the ability of integrin to bind ligands is contingent on the binding of a divalent
cation – Mg2+ or Mn2+ – at the MIDAS site.32 Additionally, isolated integrin I-domains
preserve the same ligand-binding abilities as the full length integrins.

b subunit. Each of the 8 b subunits contain an I-like domain similar to those
which are found in α subunits. b subunits also contain a plexin/semaphoring/integrin
(PSI) domain, a hybrid domain, four epidermal growth factor (EGF) repeats, and a
membrane proximal b tail domain (bTD).33 The image in Figure 3 below depicts the
overall structure of an integrin heterodimer formed from the association of an α and b
subunit.
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Figure 3: Integrin Structure. From Barczyk M., Carracedo S. & Gullberg D. Integrins.
Cell Tissue Res. 2010; 339(269). Reprinted with permission from Elsevier. Integrins are
composed of an α and b subunit, held together by non-covalent interactions. Integrins
have a large extracellular portion, short transmembrane domain, and short cytoplasmic
tail.

The b2 integrins
There are four members within the b2 integrin subfamily: aLb2 (CD11a/CD18;
LFA-1), aMb2 (CD11b/CD18, MAC-1), aXb2 (CD11c/CD18), and aDb2 (CD11d/CD18).
Uniquely, the b2 integrins are only expressed on the surface of leukocytes and are not
found on other cell types, hence their labeling as the leukointegrins.34 While each
different type of leukocyte expresses its own unique combination of integrins, the b2
integrins are the most abundantly expressed on their surfaces.35 Leukocytes rely on the
19

b2 integrins to carry out several essential mechanisms throughout the inflammatory
response. These include cell interactions with endothelial cells during extravasion,
interaction with the extracellular matrix within the tissue, cell adhesion, cell migration,
phagocytosis, and the cell’s ability to receive and respond to important inflammatory
signals.35, 36 Because of their selective expression on leukocytes and their heavy
involvement throughout the inflammatory response, the b2 integrins have become very
attractive therapeutic targets for a number of diseases. This thesis focuses on one
particular member of the b2 integrin subfamily, integrin aDb2, and its potential role in
chronic inflammation.
Integrin aDb2. Integrin aDb2 (CD11d/CD18) is the most recently discovered
member of the b2 subfamily. While much remains unknown about this integrin, recent
studies point to its key functions in inflammation, pathogen response, and tissue injury
in experimental animals.37 The crystal structure for integrin aDb2 currently remains
unsolved, but the integrin does share significant homology in sequence with the other
leukointegrins which are well-studied. The amino acid identities are very similar
between aM, aX, and aD, sharing 60-66% homology, while only 35% amino acid identify is
shared with aL.38 Current ligands identified for integrin aDb2 include ICAM-3, VCAM-1,
fibrinogen, fibronectin, plasminogen, CYR6 and most recently CEP, a ligand found at
sites of inflammation.39, 40 Which types of human leukocytes express integrin aDb2
remains controversial but current research shows low to moderate expression on
neutrophils and circulating monocytes, with upregulation on tissue macrophages –
especially those within inflammatory lesions related to diseases such as atherogenesis
and diabetes.
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Role of CEP-aDb2 Interaction in Inflammation
During inflammation, the generation of reactive oxygen species causes oxidative
modifications to surrounding lipids and proteins. One such modification is 2-(ωcarboxyethyl) pyrole, abbreviated CEP, an adduct to proteins and phospholipids
generated from oxidation of docosahexaenoic acid (DHA).41 CEP generated in-vivo is
biologically active and progressively accumulates under inflammatory conditions.42
Interestingly, Yakubenko et. al recently proposed that during the first wave of
inflammation, the oxidative insult generated by neutrophils significantly contributes to
the formation of CEP and its addition onto surrounding components of the extracellular
matrix.43 After confirming CEP upregulation in inflammatory tissue in mice, they used
CEP-blocking antibodies to demonstrate that early neutrophil invasion remained
unaffected, while the subsequent appearance of macrophages was significantly
reduced. The also showed that in the absence of neutrophils, the amount of CEP at the
inflammatory site was significantly reduced. Importantly, they further demonstrated that
CEP modifications to the extracellular matrix serves as a ligand for integrin aDb2, which
is dramatically upregulated on inflammatory macrophages.44 As overexpression of this
integrin causes excessive adhesion, this mechanism of integrin aDb2 upregulation is
believed to function as a brake signal which prevents further cell migration and thus
promotes macrophage retention in inflamed tissue, especially during chronic
inflammatory reactions where there is an abundance of CEP-decorated extracellular
matrix proteins.45
Other macrophage receptors also recognize CEP for the purpose of binding and
removing these CEP-tagged, damaged extracellular matrix components.42 However,
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blocking the interaction between CEP-aDb2 is of high interest because of the unique
expression pattern of aDb2 being low to moderate expression on circulating monocytes
and significant upregulation on inflammatory macrophages.44 Thus, creation of a
specific CEP-aDb2 inhibitor may have the potential to target and prevent macrophage
accumulation and retention at sites of inflammation, which has very important clinical
applications for prevention and treatment of chronic inflammatory diseases.
P5 Peptide
These important discoveries were followed with another study by Cui et. al. which
successfully identified a specific aDb2 -CEP inhibitor capable of preventing macrophage
accumulation, named the P5 peptide.46 The P5 peptide was identified through a
specially designed peptide library, Biacore detected protein-protein interactions, and
integrin transfected HEK 293 adhesion assays. The P5 peptide is 15 amino acids in
length, with the amino acid sequence reading “GDAFDGFDFGDDPSD.” The presence
of 6 aspartic acid residues in the sequence confers a strong overall negative charge to
the peptide. The P5 peptide was shown to specifically bind to integrin aDb2 and not to
other leukointegrins such as aXb2 or aMb2, which share very similar amino acid
sequences. Using a thioglycollate-induced peritoneal model of inflammation, injection of
cyclic P5 peptide reduced macrophage accumulation in WT mice by 3-fold, but had no
effect in aD-deficient mice.46 Additional experiments with the P5 peptide were very
promising, as injection of cyclic P5 peptide into WT mice placed on a high fat diet
prevented macrophage accumulation in an aDb2-dependent manner in the adipose
tissue.46 Cleary, the P5 peptide prevents macrophage integrin aDb2-mediated adhesion
to CEP both in-vivo and in-vitro. These findings point to the critically important role of
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integrin aDb2 in macrophage accumulation and retention during inflammation, and
identify the P5 peptide as a potential inhibitor to prevent chronic inflammatory disease.
This thesis aims to identify the amino acids of integrin aDb2 which facilitate
binding to the P5 peptide and similarly to CEP. Identification of these amino acids not
only provides critical information for the development of a clinically relevant inhibitor of
macrophage retention at the site of chronic inflammation, but also provides insight into
the molecular interaction between integrin aDb2 and CEP.
Hypothesis
We propose that non-conserved, basic amino acids of the integrin aDb2 located
near the MIDAS site of the I-domain are responsible for binding to the P5 peptide and
likewise to CEP.
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CHAPTER 2. EXPERIMENTAL PROCEDURES
Identification of Amino Acids for Mutation
NCBI Protein BLAST
To identify potential aD I domain amino acids for mutation, a NCBI protein BLAST
was performed which compared the human aD I domain amino acid sequence to that of
the aM I domain. As the P5 peptide carries a negative charge and has been shown to
not bind to aMb2, non-homologous basic amino acid residues of the aD I domain were of
interest.
3D Protein Structure Homology Modeling
To narrow the selection of potential amino acids for mutation, a previously
generated computer model was used to determine the location of each selected amino
acid of the aD I domain. Additionally, FirstGlance in Jmol software was used to identify
the location for corresponding amino acids of aM. In each case, basic non-homologous
amino acid residues near the aD I domain MIDAS site were of important interest as well
as those contributing to an area of positive charge.
Introduction of Mutation
Plasmid Construct
Recombinant human aD I domain DNA sequence encoding residues (D147A331) was contained in pET-15b vector. The aD I-domain DNA sequence was inserted
at the NdeI restriction site for transcription by bacterial T7 polymerase which recognizes
the T7 promoter of the expression vector. Expression of the recombinant aD I domain
sequence was under control of the lac operon and the vector provided resistance to
ampicillin.

24

Generation of Mutagenic Primers
Mutagenic primers were generated and analyzed using Oligo Primer Analysis
Software version 6. The upper and lower primer sequences used for generating each
mutation are shown below in Table 1.

Table 1: Primers Used for PCR Site Directed Mutagenesis. The mutagenic primer
sequences for each mutation designed with Oligo Software.
Amino Acid

K180

R189

K205

HHK 223-225

K233

K246

Upper Primer Sequence

Lower Primer Sequence

5’-GCAGTACTCAAACCTCC
TGGCGATCCACTTCACCTT
CACC-3’

5’-GGTGAAGGTGAAGTGGAT
CGCCAGGAGGTTTGAGTACT
GC-3’

5’CCGTGAACGTCAGGCCTAGCA
GTTGGACGATGGG-3’

5’-GGCTCGGGCTGGTCTGGA
ATTGGGTGAAGG-3’

5’-CCCATCGTCCAACT
GCTAGGCCTGACGTTC
ACGG-3’

5’-CCGTGAACGTCAGGCCT
AGCAGTTGGACGATGGG-3’

5’-GGTGACACAGCTA
TTTAATATTACGAATGG
GGCCCGAAAAAG-3’

5’-CTTTTTCGGGCCCCATT
CGTAATATTAAATAGCTGT
GTCACC-3’

5’GCCCGAAAAAGTGCC
GCGAAGATCCTCATTG
TC-3’

5’-GACAATGAGGATCTTCG
CGGCACTTTTTCGGGC-3’

5’-GATGGGCAGAAGTA
CGCAGACCCCCTGGA
ATACAG-3’

5’-CTGTATTCCAGGGGGTCT
GCGTACTTCTGCCCATC-3’

The upper and lower mutagenic primers shown above in Table 1 were obtained from
Integrated DNA Technologies Inc. (Coralville, Iowa).
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PCR Site-Directed Mutagenesis
PCR Site-Directed Mutagenesis was performed using the QuikChange II SiteDirected Mutagenesis Kit following the manufacturer’s instructions (Agilent
Technologies, Catalog # 200523). The kit components were thawed on ice and the
sample reactions were prepared in a thin-walled PCR tube as shown below in Table 2.

Table 2: PCR Sample Reaction Components. The listed quantity or volume of each
component was added to a thin walled PCR tube for generation of each mutagenic
construct.
Component

Quantity/Volume

10x Reaction Buffer

5 µL

dsDNA Template

50 ng

Upper Mutagenic Oligonucleotide Primer

125 ng

Lower Mutagenic Oligonucleotide Primer

125 ng

dNTP Mix

1 µL

ddH20

to final volume of 50 µL

After each of the sample reaction components were placed in the tube and gently
mixed, 1 uL of PfuUltra HF DNA polymerase provided with the kit was added to the
reaction. The sample reaction was then placed in a thermal cycler (BioRad T100) and
cycled through the following conditions shown in Table 3 below as recommended by the
manufacturer.
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Table 3: QuikChange II Site-Directed Mutagenesis Cycling Conditions. Each
mutagenic construct created by PCR Site-Directed Mutagenesis was cycled through the
listed conditions.
Segment

Number of Cycles

Temperature

Time

1

1

95°C

30 seconds

95°C

30 seconds

55°C

1 minute

68°C

5 minutes 30 seconds

2

3

18

1

4°C

ꝏ

Following the temperature cycling, the sample reaction was placed on ice for 2 minutes
to cool. To digest unmutated template DNA, 1 uL of Dpn I restriction enzyme was added
directly to the sample and gently mixed. The reaction was incubated at 37°C for 1 hour
before transformation of XL1-B cells.
XL1-B Transformation
XL1-B Supercompetent cells were transformed following the manufacturer’s
protocol (Agilent Technologies, Catalog # 930236). The cells were first thawed on ice
for 30 minutes, followed by the addition of 1 uL of Dpn I-treated DNA from the PCR
sample reaction. The transformation reaction was gently swirled and placed on ice for
30 minutes. The transformation reaction was then heat-pulsed for 45 seconds in a 42°C
water bath and immediately placed on ice for 2 minutes. Preheated 42°C SOC medium
(Thermo Scientific, Catalog # 15544034) was added to the reaction, followed by an
incubation at 37°C for 1 hour with shaking at 225 rpm. After incubation, the
transformation reaction was plated on LB agar containing 100 ug/mL ampicillin and
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placed in a 37°C incubator overnight. The next day, single colonies were selected from
the transformation plate, individually placed in 3 mL TB media containing 100 ug/mL
ampicillin, and cultured overnight.
DNA Isolation
DNA was isolated from the XL1-B cell culture using the QIAprep Spin Miniprep
Kit by Qiagen (Catalog # 27104). Following the manufacturer’s instructions, 3 mL of
bacterial cell culture was placed in a table-top microcentrifuge (Sorvall Legend Micro
21R Refrigerated Centrifuge, Catalog # 75002447) and spun at 8000 rpm for 3 minutes
at room temperature. The pelleted bacterial cells were resuspended in 250 uL Buffer
P1. Buffer P2 was then added, the sample was mixed, and Buffer N3 was added. The
sample was immediately mixed by inverting the tube and placed in the microcentrifuge
for 10 minutes at 13,000 rpm. The supernatant was collected and transferred to a
QIAprep 2.0 spin column and centrifuged for 1 minute. Buffer PE was added to the spin
column and then centrifuged for 1 minute. All buffers mentioned were provided with the
kit. To move residual wash buffer, the spin column was centrifuged again for another
minute. To elute the DNA, the spin column was transferred to a clean microcentrifuge
tube and 50 uL of warm water was added to the center of the spin column. The column
was allowed to stand for 1 minute and then centrifuged for one minute. DNA
concentration was determined by spectrometer (Synergy H1 Hybrid Multi-Mode
Microplate Reader, BioTek Instruments).
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Protein Expression
BL21 Transformation
BL21(DE3) competent cells were transformed according to manufacturer’s
instructions (Agilent Technologies, Catalog # 200133). Competent cells were thawed on
ice for 30 minutes. Next, 50 ng of DNA containing the desired mutation was added to
the cells and incubated on ice for 30 minutes. After incubation, the transformation
reaction was heat-pulsed for 45 seconds in a 42°C water bath. The reaction was placed
on ice for 2 minutes, followed by addition of preheated 42°C SOC medium to the cells.
The cells were incubated at 37°C for 1 hour with shaking at 225 rpm. Following
incubation, cells were plated on LB agar containing 100 ug/mL ampicillin and incubated
at 37°C overnight.
Cell Culture
A single colony taken from the transformation plate was placed in 3mL TB media
containing 100 ug/mL ampicillin. The cells were cultured for 7-9 hours at 37°C with
shaking at 225 rpm. Next, 200 uL of the culture was transferred to 200 mL TB media +
100 ug/mL ampicillin and grown overnight. The next morning, the 200 uL of culture was
brought up to 2 liters by addition of 1.8 L of fresh TB media + 100 ug/mL ampicillin. The
2 liters were split evenly between 4 flasks and cultured at 37°C with shaking for 2-2.5
hours until reaching an optical density of 1.
Protein Expression with IPTG
Recombinant protein expression was induced by addition of isopropyl β-dthiogalactopyranoside (IPTG) to the bacterial culture for a final concentration of 1mM.
Cells were incubated at 37°C with shaking for another 4 hours.
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Protein Isolation
Bacterial Cell Lysis
After induction of protein expression, bacterial cell cultures were centrifuged at
6,000 RPM (3951 RCF) and 4°C for 20 minutes. The supernatant was discarded and
the bacterial cell pellet was lysed by resuspension in 1% Triton + PBS. The bacterial cell
lysate was frozen overnight at -80°C. The next day, the bacterial lysate was thawed in a
37°C water bath. To destroy chromatin, lysate was placed on ice and sonicated twice
for 2 minute intervals. After sonification, the lysate was centrifuged at 15,000 rpm
(16556 RCF) for 30 minutes at 4°C. The supernatant containing protein was collected
and the pellet discarded.
Ni-NTA Column Chromatography
Proteins were isolated using Ni-NTA Column Chromatography. To stabilize the
protein and block non-specific binding, imidazole and NaCl were added to the
supernatant for a final concentration of 10mM imidazole and 500mM NaCl. The
supernatant containing protein was then incubated with HisPur Ni-NTA Superflow
Agarose (Thermo Scientific, Prod# 25214) at 4°C for 1 hour with gentle rocking. After
incubation, the sample was placed in a centrifuge and spun at 4°C and 1200 rpm for 10
minutes (Heraeus™ Multifuge™ X3 Centrifuge, Thermo Scientific). The bottom layer
containing Ni-NTA agarose bound to protein was collected using a pipette and
transferred to a Poly-Prep Chromatography Column (Bio-Rad Laboratories, Catalog
#731-1550) for isolation. Once the Ni-NTA agarose bound to protein was loaded into the
column, the column was washed with 40mL of 20mM imidazole or until the eluent had
reached an optical density of less than 0.1. This was followed by washing with 20 mL of
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60mM imidazole or until the eluent had reached an optical density of less than 0.05. The
final wash step was with 20 mL of 80mM imidazole or until the eluent reached an optical
density of less than 0.01. After completing the washing steps, the protein was eluted
with 5 mL 250mM imidazole into 5 separate samples of 1mL each. The pre-dialysis
concentration of protein in each sample was determined by spectrometer (Synergy H1
Hybrid Multi-Mode Microplate Reader, BioTek Instruments).
Protein Dialysis
Isolated protein samples were combined and placed in dialysis tubing by
Fisherbrand (# 21-152-10). For the first phase of dialysis, the proteins were placed in
500mL PBS + 1M NaCl for 30 minutes at 4°C with gentle stirring. Next, the proteins
were switched into 500mL PBS + 500mM NaCl at 4°C with gentle stirring and left
overnight. The next morning, the proteins were placed into 500mL 20mM Hepes +
150mM NaCl for 4 hours at 4°C with gentle stirring. The protein was collected and postdialysis protein concentration was checked with spectrometer (Synergy H1 Hybrid MultiMode Microplate Reader, BioTek Instruments).
Protein Analysis
SDS-PAGE
The amount and purity of protein was visualized by performing SDS-PAGE. For
each sample, 6 uL of 5x SDS loading buffer was added a 24 uL sample of the protein.
The protein samples were heated for 5 minutes at 100°C. The protein ladder (Precision
Plus Protein™ Dual Color Standards, 500 µl #1610374, BioRad) was added to the first
well of a 15% polyacrylamide gel, followed by loading of each protein sample into
subsequent wells. After running the gel and separation of protein, the gel was washed
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with a 10% acetic acid, 50% methanol, and 40% water solution. The gel was stained
with a 90% water, 10% acetic acid solution containing Coomassie blue R250,
Coomassie blue G250, and amido black.
BCA Assay
Protein concentrations were also measured using the Pierce BCA Protein Assay
Kit (Thermo Scientific, Product # 23227) following the manufacturer’s instructions.
Standards ranging from 0 ug/mL to 2000 ug/mL were prepared from Bovine Serum
Albumin provided with the kit and diluted with buffer containing 20mM Hepes and
150mM NaCl. Then, 25 uL of each standard and protein sample were added to
individual wells of a 96 well plate (Immulon, 2HB). After adding standards and samples
into the plate, 200 uL of working reagent provided by the kit was added to each well
containing a standard or samples. The plate was incubated at 37°C for 45 minutes.
Following incubation, the plate was allowed to cool and absorbance at 562 nm was
measured for each standard and sample using the Synergy H1 Hybrid Multi-Mode
Microplate Reader from BioTek Instruments. The absorbance and known
concentrations of each standard were used to generate a standard curve on Microsoft
Excel. The concentration of each sample protein was calculated using the generated
standard curve.
Surface Plasmon Resonance Assays
The binding abilities of wild-type aD I domain protein and mutant aD I domain
protein to various ligands were assessed through surface plasmon resonance assays
using the ForteBio K2 Octet system.
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Streptavidin Biosensor Assays
To test protein binding to the P5 peptide, biotinylated P5 peptide was
immobilized onto an activated streptavidin biosensor chip from ForteBio. Preparation of
the streptavidin chip and recording of sensorgrams were carried out according to
manufacturer’s instructions. Each streptavidin biosensor was soaked in buffer
containing 20mM Hepes, 150mM NaCl and 1mM CaCl2 to remove the protective
surface. Proteins to be assayed were diluted to desired concentrations in buffer
containing 20mM Hepes, 150mM NaCl, 1mM CaCl2, 1mM MgCl2 and 0.02% Tween.
Amine Reactive (ARG2) Biosensor Assays
Amine Reactive (ARG2) ForteBio biosensor chips were used to test protein
interaction with CEP. The protective surface of the ARG2 biosensor was removed by
soaking in buffer containing 20mM Hepes, 150mM NaCl and 1mM CaCl2. The ARG2
biosensors were activated with N-hydroxysulfosuccinimide (s-NHS) and 1-Ethyl-3-(3(dimethylamino)propyl)carbodiimide (EDC). Ligands to be tested were placed in Sodium
Acetate solution adjusted to pH 5 and immobilized onto the activated biosensor surface.
Unreacted sites on the biosensor surface were quenched with 1M Ethanolamine.
Proteins were assayed in buffer containing 20mM Hepes, 150mM NaCl, 1mM CaCl2,
1mM MgCl2 and 0.02% Tween.
Cell Adhesion Assays
Mutant I-domain which showed a decrease in binding to P5 peptide was selected
for further analysis by cell adhesion assay.
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Cell Culture
The aDb2.-transfected Human embryonic kidney 293 cells were maintained in
DMEM-F12 (BioWhittaker, Walkersville, MD) supplemented with 10% FBS, 2 mM
glutamine, 15 mM HEPES, 0.1 mg/ml streptomycin and 0.1 unit/ml penicillin.
Cell Transfection
Site-directed mutagenesis of the aD subunit was performed using the QuickChangeTM
Mutagenesis Kit. The pcDNA3.1/Neo(-) construct containing DNA encoding the fulllength aD subunit was modified by site-directed mutagenesis using two mutagenic
primers containing the desired mutation. Cells were stably transfected with pcDNA3.1
plasmids with inserted b2 and wild-type or mutant aD using LipofectamineTM 2000
reagent (Invitrogen, San Diego, CA). After 48 h at 37°C in 5% CO2, cells were
harvested and cultured in medium with 500 mg/ml G418 (Invitrogen) and 250 mg/ml
Hygromycin (Invitrogen). After 14 days, surviving cells were collected, sorted and
analyzed using flow cytometry.
Cell Sorting
FACS analyses were performed to assess the expression of receptors on the
surface of the cells transfected with aDb2 integrin. The cells were incubated with anti-aD
polyclonal Ab and anti-b2. mAb IB4 and analyzed using a FACScanä (Beckton
Dickinson) as described. The populations of cells expressing similar amounts of aDb2
and aDb2 K246 mutant were selected by fluorescence activated cell sorting using a BD
Biosciences FACS Vantage Instrument.
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Cell Adhesion
For adhesion assays, 96-wells tissue culture plates (Costar, Cambridge, MA)
were coated with CEP-BSA and fibrinogen for 3 h at 37°C. The wells were post-coated
with 0.5% PVA for 1 h at 22°C to block non-specific binding to the plate. The transfected
HEK293 cells in DMEM/F-12 were labeled with 10 mM Calcein AM (Molecular Probes,
Eugene, OR) and incubated at 37°C for 30 minutes. The cells were then washed with
DMEM/F-12 and then diluted with HBSS to 1x106/ml. After washing the plate 3 times
with PBS, 50 uL of cells were added to each well, followed by incubation for 30 minutes
at 37°C and 5%CO2. 200 uL PBS added to each well to wash the cells. Then, the buffer
was removed by shaking out and the fluorescent signal on the plate was assessed.
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Experimental Design Flow Through

Identify potential amino acids involved in
binding to P5 peptide through comparable
analysis of sequences and 3D structures of
aD and aM I domains

Generate constructs for the expression of
mutated I domain in E. Coli using PCR sitedirected mutagenesis

Express mutated proteins through molecular
cloning and test their binding to P5 peptide
through ForteBio protein-protein assay

Select mutants that show a decreased
binding to P5 for further analysis

Generate constructs to introduce the
selected mutations in the entire aDb2
sequence

Transfect HEK 293 cells with the mutated
aDb2 constructs and test the binding to CEP
peptide applying adhesion assay
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CHAPTER 3. RESULTS
Selection of aD I-domain Amino Acids for Analysis
The goal of this project was to identify amino acids of human macrophage
integrin aDb2 which facilitate binding to P5 peptide. Our focus was the aD subunit Idomain as this domain is responsible for ligand binding. Because the P5 peptide carries
a strong negative charge, we propose that basic amino acid residues of the aD I-domain
facilitate the binding P5 peptide. To begin compiling a list of aD I-domain amino acids
potentially involved in the interaction with P5, a comparative analysis using NCBI
BLAST was performed comparing the amino acid sequences of aD and aM. Basic amino
acid residues of the aD I-domain which are not shared with aM were of interest as the P5
peptide does not bind to other closely related members of the integrin family by design,
including aM which shares around 60% homology. From the aD-aM BLAST analysis, 10
such amino acids were selected for potential analysis as shown in Figure 4.
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Figure 4. Comparative BLAST analysis. NCBI Blast analysis comparing amino acid
sequences of aD I-domain to aM I-domain. The aD I-domain is underlined. The 10
nonhomologous, basic amino acid residues of aD I-domain identified are highlighted in
yellow.

Next, a computer model generated by Christopher Ardell (shown in Figure 5) of
the aD I-domain was used to visualize an approximate location for each of the selected
amino acids. Using this model, K180 was selected for potential analysis in addition to
the 10 amino acids identified from the BLAST comparison.
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Figure 5: Predicted Structure of the aD I-domain. Computer generated model of the
aD I-domain. Areas of positive charge are shown in blue and negative charge is shown
in red.

Additionally, the FirstGlance in Jmol software was used to find the location of each
corresponding aM amino acid for the 10 selected aD amino acids. The model for aM was
generated using PDB identification code 1IDO. The location of each corresponding aM
amino acid was used to predict the location of the amino acids in aD. Amino acids
located near the MIDAS site as well as amino acids located on the surface were of great
interest. Of the 11 amino acids selected for potential analysis, 9 appeared to have
important structural relevance and 8 amino acids were officially selected for
mutagenesis: K180, R189, K205, H223, H224, H225, K233, and K246. A summary of
this selection process is shown in Table 4 below.

39

Table 4: Process of Selecting aD I-domain Amino Acids for Mutation. Amino acids
were selected for analysis based on the comparative analysis with aM and the structural
analysis of the aD I domain. Positively charged amino acids are shown in blue,
negatively charged amino acids are shown in red.
Identification Method

aD I-domain amino acids
selected for potential
analysis

aM BLAST

Predicted aD
Structure

K180

-

R189

Corresponding
amino acid in aM

Selected for
Analysis

✓

R181

✓

✓

✓

Q190

✓

K205

✓

✓

L206

✓

H223

✓

✓

N224

✓

H224

✓

✓

I225

✓

H225

✓

✓

T226

✓

K233

✓

✓

F234

✓

K246

✓

✓

G247

✓

H272

✓

✓

D273

-

K297

✓

-

Q298

-

K309

✓

-

N310

-

The 8 amino acids chosen were subjected to PCR site-directed mutagenesis to create 6
mutant versions of the human aD I-domain protein. As amino acids H223, H224, and
K225 are located in tandem, they were substituted together to create Mutant HHK223225[NIT]. The five other chosen amino acids were individually substituted to generate
their own mutant I-domains. Each of the selected aD amino acids were substituted for
the corresponding amino acid in aM. In the case that the aM amino acid had a bulky side
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group or carried a negative charge, the aD amino acid was substituted for alanine (A).
Mutations to the DNA sequence were carefully chosen using as few DNA base
substitutions as possible to create the desired mutation. The DNA primers designed to
create the mutation during PCR Site-Directed Mutagenesis were generated using Oligo
Software. The amino acid substitution, DNA base substitution and primer sequences
used to generate each mutagenic construct are shown below in Table 5.

Table 5: Generation of Mutant Constructs. Table 5 shows the amino acid
substitutions and DNA base substitutions chosen to generate each of the mutagenic
constructs. Additionally, the upper and lower primer sequences designed for PCR-Site
Directed Mutagenesis to generate the mutation are listed.

Mutant

Amino Acid
Substitution

DNA Base
Substitution

Upper Primer
Sequence

Lower Primer Sequence

K180

K180 à A180

AAG à GCG

5’GCAGTACTCAAACCTCCTG
GCGATCCATTCACCTTCAC
C-3’

5’GGTGAAGGTGAAGTGGATC
GCCAGGAGGTTTGAGTACT
GC-3’

R189

R189 à Q189

CGG à CAG

5’CCGTGAACGTCAGGCCTA
GCAGTTGGACGATGGG-3’

5’GGCTCGGGCTGGTCTGGAA
TTGGGTGAAGG-3’
5’CCGTGAACGTCAGGCCTAG
CAGTTGGACGATGGG-3’

K205

K205 à L205

AAA à CTA

5’CCCATCGTCCAACTGCTAG
GCCTGACGTTCACGG-3’

HHH223225

HHK 223-225
à NIT 223-225

CATCATAAGà
AATATTACG

5’GGTGACACAGCTATTTAAT
ATTACGAATGGGGCCCGA
AAAAG-3’

5’CTTTTTCGGGCCCCATTCGT
AATATTAAATAGCTGTGTCA
CC-3’

K233

K233 à A233

AAG àGCG

5’GCCCGAAAAAGTGCCGCG
AAGATCCTCATTGTC-3’

5’GACAATGAGGATCTTCGCG
GCACTTTTTCGGGC-3’

K246

K246 à A246

AAA à GCA

5’GATGGGCAGAAGTACGCA
GACCCCCTGGAATACAG-3’

5’CTGTATTCCAGGGGGTCTG
CGTACTTCTGCCCATC-3’
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Mutants K180[A] and R189[Q] are Comparable to Wild-Type I-domain in Binding P5
Amino acid K180 was selected for analysis despite a basic residue being
conserved in aM because it was shown to create an area of significant protruding
positive charge in the computer-generated model (Figure 5) of the aD I-domain near the
MIDAS site. The corresponding amino acid in aM, R181, is also located in the same
area providing more evidence that the predicted location of K180 is correct. We
questioned if aD amino acid K180 might work together with amino acids K205 and K246,
which are located nearby and contribute significant positive charge in a manner similar
to K180 as shown in Figure 5.
As the corresponding amino acid in aM is also basic, amino acid K180 was
substituted for alanine to generate the K180[A] mutant I-domain construct. The
construct was sequenced to confirm presence of the K180[A] mutation and then
transformed into E.coli BL21 cells. The cells were cultured and protein expression was
induced by addition of IPTG. The expressed K180[A] I-domain was then isolated using
Ni-NTA affinity chromatography. After isolation, the collected protein sample was placed
in a 3-step dialysis to change the buffer required for P5 binding testing. Wild-type Idomain also was expressed and isolated in the same manner to later serve as a control
in the P5 binding analysis. The K180[A] mutant was expressed and isolated four
separate times and binding to P5 was tested for each of the four isolations.
The concentration of isolated Wild-Type and K180[A] I-domain protein was
determined by Pierce BCA Assay to be 136 ug/mL and 102.15 ug/mL, respectively. To
analyze the purity of protein, a sample of the isolated Wild-Type I-domain and K180[A]
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proteins were ran on a 15% acrylamide electrophoresis gel which is shown below in
Figure 6.

Figure 6: SDS-polyacrylamide gel electrophoresis (15%) for isolated WT and
K180[A] I-domain protein. Lane 1: Protein Standards. Lane 2: Pre-Dialysis WT Idomain. Lane 3: Post-Dialysis WT I-domain. Lane 4: Pre-Dialysis K180[A] I-domain.
Lane 5: Post-Dialysis K180[A] I-domain.

The purified wild-type and K180[A] I-domain proteins were assessed for their
ability to bind P5 peptide at two different concentrations, 1.26 µM and 2.5 µM for wildtype and 1.1 µM and 2.21 µM for K180[A], using the ForteBio Octet Protein-Protein
assay. Linear biotinylated P5 peptide was immobilized onto a Streptavidin biosensor
chip. The ability of wild-type and K180[A] to bind to P5 was measured in real-time by the
ForteBio Octet system, as shown in the representative Sensorgram below in Figure 7.
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Figure 7. WT and Mutant K180 I-domain binding to P5. Representative ForteBio
Octet Protein-Protein assay Sensorgram of WT and K180[A] binding to immobilized P5
on a streptavidin biosensor. Association of I-domain binding to P5 occurs from Time 0 to
360 seconds, followed by the dissociation of I-domain from P5 until 700 seconds.

As shown above in Figure 7, the ability of K180[A] to bind P5 peptide was very
similar to the Wild-Type aD I domain. The shape of the binding curve for both wild-type
and K180[A] is rectangular hyperbola and demonstrates non-cooperative, I-domain
concentration dependent binding to P5 with moderate affinity. As P5 binding was
unaffected by the mutation, amino acid K180 is not involved in the P5 binding
interaction.
Amino acid R189 was selected as a basic amino acid is not conserved in this
position in aM. Additionally, the proposed structure of aD shown in Figure 5 places this
amino acid as a part of Pocket 1 along with amino acids H223, H224, K225, and K233.
Together, these amino acids are believed to form a relatively large area of positive
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charge which made each of them of high interest in binding to the negatively charged
P5 peptide.
Amino acid R189 was substituted for Glutamine(Q), the corresponding residue in
aM. The R189[Q] mutant was expressed and isolated two separate times and binding to
P5 was tested for each of the two isolated protein samples. The concentrations of
protein used in the R189[Q] Sensorgram in Figure 9 were determined using BCA Assay
concentrations of 164.9 ug/mL for Wild-Type I-domain and 238.09 ug/mL for the
R189[A] mutant. Wild-Type I-domain and R189[Q] proteins was ran on a 15%
acrylamide electrophoresis gel which is shown below in Figure 8.

Figure 8. SDS-polyacrylamide gel electrophoresis (15%) for isolated WT and
R189[Q] I-domain protein. Lane 1: Protein Standards. Lane 2: Post-Dialysis WT Idomain. Lane 3: Post-Dialysis R189[Q] I-domain.
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The R189[Q] I-domain protein was tested for its ability to bind P5 peptide compared to
Wild-Type I domain by ForteBio Octet Protein-Protein assay. A representative
Sensorgram from the ForteBio Octet assay for Wild-Type and mutant R189[Q] Idomains binding to P5 peptide is shown below in Figure 9.

Figure 9. WT and Mutant R189[Q] I-domain binding to P5. Representative ForteBio
Octet Protein-Protein assay Sensorgram of WT and R189[Q] binding to immobilized P5.
I-domain binding to P5 occurs from Time 0 to 360 seconds, followed by the dissociation
of I-domain and P5 until 700 seconds.
R189[Q] I-domain demonstrated slightly reduced but similar maximum binding to P5
peptide as compared to the Wild-Type. Sensorgram binding curves demonstrate
moderate affinity to P5 and concentration dependent binding for both Wild-Type and
R189[Q] mutant. Amino acid R189 is not involved in binding to P5 as only a small
difference in binding is observed after mutation.
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Mutants K205[L], HHK223-225[NIT] and K233[A] Demonstrated an Increase in P5
Binding Compared to Wild-Type I-domain
Amino acid K205 was selected as a basic amino acid residue is not conserved in
this position in aM. In the proposed structure of the aD I-domain shown in Figure 5,
amino acid K205 creates an area of significant positive charge protruding from the
surface making it of important interest.
The K205 amino acid was substituted for Leucine (L), the corresponding amino
acid in aM. The K205[L] mutant was expressed and purified two separate times for P5binding analysis. For ForteBio analysis, the concentration of isolated I-domain protein
was confirmed by Pierce BCA Assay to be 108.75 ug/mL for Wild-Type I domain and
119.6 ug/mL for K205[L] I domain. The 15% acrylamide electrophoresis gel shown
below in Figure 10 shows the purity of isolated Wild-Type I-domain and K205[L] I
domains.

Figure 10. SDS-polyacrylamide gel electrophoresis (15%) for isolated WT and
K205[L] I-domain protein. Lane 1: Protein Standards. Lane 2: Post-Dialysis WT Idomain. Lane 3: Post-Dialysis K205[L] I-domain.
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The isolated wild-type and K205[L] I-domain proteins were assessed for their ability to
bind P5 peptide by ForteBio Octet Protein-Protein. A representative Sensorgram from
the ForteBio Octet assay testing three different concentrations of wild-type I-domain
(1.29 µM, 2.59 µM, and 3.88 µM) and mutant K205[L] I-domain (1.25 µM, 2.50 µM, and
3.75 µM) binding to P5 peptide is shown below in Figure 11.

Figure 11. WT and Mutant K205[L] I-domain binding to P5. Representative ForteBio
Octet Protein-Protein assay Sensorgram of WT and K205[L] binding to P5 peptide on a
streptavidin biosensor. Association of I-domain and P5 during occurs from 0 to 300
seconds, followed by the dissociation of I-domain and P5 until 580 seconds.

As shown in Figure 11, K205[L] I-domain demonstrated increased binding to P5 peptide
compared to the Wild-Type I-domain. This increased binding can be explained by slight
conformational change in the I-domain structure due to the redistribution of surface
charge. However, this result clearly demonstrates that amino acid K205 is not involved
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in P5 binding to aD I-domain, as the K205 substitution to leucine did not cause a
decrease in the level of binding observed.
Amino acids H223, H224, and K225 were chosen because a basic amino acid is
not conserved in these positions in aM. Additionally, these amino acids are believed to
form an integral part of Pocket 1, an area of significant positive charge in the aD Idomain shown in Figure 5. The role of amino acids composing this positively charged
Pocket 1 were of high interest in binding to the negatively charged P5 peptide. As amino
acids H223, H224, and K225 are located in tandem, they were substituted for the
corresponding residues in aM, Asparagine (N), Isoleucine (I), and Threonine (T)
respectively to create the HHK223-225[NIT] mutant aD I-domain. The ability of the
HHK223-225[NIT] mutant I-domain to bind P5 peptide was tested using two separately
expressed and purified protein samples. Pierce BCA Assay determined to protein
sample concentrations to be 133 ug/mL for Wild-Type I-Domain and 144 ug/mL for
HHK223-225[NIT] I-domain. A 15% acrylamide electrophoresis gel containing samples
of the isolated Wild-Type and HHK223-225[NIT] I-domain proteins is shown below in
Figure 12.
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Figure 12. SDS-polyacrylamide gel electrophoresis (15%) for isolated WT and
HHK223-225[NIT] I-domain protein. Lane 1: Protein Standards. Lane 2: Post-Dialysis
WT I-domain. Lane 3: Pre-Dialysis HHK223-225[NIT] I-domain. Lane 4: : Post-Dialysis
HHK223-225[NIT] I-domain.

The representative ForteBio sensorgram displaying 4 different concentrations of
isolated wild-type I-domain (0 µM, 1.58 µM, 3.16 µM, and 4.75 µM) and HHK223225[NIT] I-domain (0 µM, 1.71 µM, 3.43 µM, and 5.14 µM) binding to P5 peptide is
shown in Figure 13 below.
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Figure 13. WT and Mutant HHK223-225[NIT] I-domain binding to P5. Representative
ForteBio Octet Protein-Protein assay Sensorgram of WT and HHK223-225[NIT] Idomain binding to P5. Association of I-domain and P5 peptide begins at time 0 until 360
seconds, followed by the dissociation of I-domain and P5 until 700 seconds.
Interestingly, the HHK223-225[NIT] mutant I-domain demonstrated a significant
increase in ability to bind P5 peptide compared to the wild-type I-domain in a
concentration dependent manner. The increased binding may be related to some
conformational change in I-domain structure. Additionally, the level of binding to P5 for
this wild-type I-domain was reduced compared to the typical levels of wild-type binding
recorded in tests with other mutants. This implies that a reduced amount of P5 peptide
was immobilized onto the streptavidin biosensor. Nevertheless, this result demonstrates
that HHK223-225 sequence is not responsible for the binding of aD I domain to P5
peptide.
Amino acid K233 was initially selected through comparative analysis of
sequences with the aM I-domain. Also, the proposed structure of aD shown in Figure 5
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places this amino acid within Pocket 1, the large region of positively charged amino
acids of great interest in potential binding to the negatively charged P5 peptide. Amino
acid K233 was substituted for Alanine (A) for expression and isolation two separate
times for P5 binding analysis. The concentration of isolated I-domain protein was 153.9
ug/mL for Wild-Type and 215.16 ug/mL for K233[A] as determined by Pierce BCA
Assay. The electrophoresis gel containing Wild-Type and K233[A] I-domain protein is
shown below in Figure 14.

Figure 14. SDS-polyacrylamide gel electrophoresis (15%) for isolated WT and
K233[A] I-domain protein. Lane 1: Protein Standards. Lane 2: Post-Dialysis WT Idomain. Lane 3: Post-Dialysis K233[A] I-domain.
The isolated wild-type and K223[A] I-domains were analyzed for their ability to bind P5
peptide by ForteBio Octet Protein-Protein assay in the same manner as described for
previous mutants. A representative Sensorgram from the ForteBio Octet assay for wildtype and mutant K223[A] I-domain binding to P5 peptide is shown below in Figure 15.
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Figure 15. WT and Mutant K233[A] I-domain binding to P5. Representative ForteBio
Octet Protein-Protein assay Sensorgram of WT and K233[A] binding to immobilized P5.
I-domain binding to P5 during Association occurs from Time 0 to 300 seconds, followed
by the dissociation of I-domain and P5 until 580 seconds.

The K233[A] mutant I-domain also demonstrated a significant increase in ability to bind
P5 peptide compared to the wild-type I-domain in a concentration dependent manner
similar to the previously described HHK223-225[NIT] mutant. Both mutants represent
substitutions in positively charged Pocket 1 (Fig.5). As we discussed above, we
hypothesize that disturbance of this Pocket leads to conformational change which
affects binding.
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Mutant K246 Demonstrated a Dramatic Reduction in Binding to both P5 Peptide and
CEP Compared to Wild-Type
Amino acid K246 was selected during the comparative sequence analysis as a
basic amino acid is not conserved in this position in aM. The proposed structure of aD in
Figure 6 shows this amino acid contributing a significant area of protruding positive
charge near the MIDAS site. Further, a Glycine is conserved in this position in both the
aM and aX integrins which do not bind to P5 peptide. Amino acid K246 was substituted
for Alanine (A), and the K246[A] mutant was expressed and isolated four separate times
to test binding to P5 peptide. The concentration of isolated I-domain protein was
confirmed Pierce BCA Assay, reading 164.917 ug/mL for Wild-Type I-domain and
148.667 ug/mL for K246[A] I-domain. Samples of the isolated Wild-Type and K246[A] Idomain proteins were ran on the SDS-Page on a 15% poly-acrylamide electrophoresis
gel shown below in Figure 16.

Figure 16: SDS-polyacrylamide gel electrophoresis (15%) for isolated WT and
K246[A] I-domain protein. Lane 1: Protein Standards. Lane 2: Post-Dialysis WT Idomain. Lane 3: Post-Dialysis K246[A] I-domain.
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Four concentrations of wild-type I-domain (0 µM, 1.96µM, 3.93 µM, and 5.89 µM) and
K246[A] I-domain (0 µM, 1.77 µM, 3.54 µM, and 5.31 µM) were tested for ability to bind
P5 peptide by ForteBio Octet Protein-Protein assay in the same manner as described
for previous mutants. A representative Sensorgram from the ForteBio Octet assay for
wild-type and Mutant K246[A] I-domain binding to P5 peptide is shown below in Figure
17.

Figure 17. WT and Mutant K246[A] I-domain binding to P5. Representative ForteBio
Octet Protein-Protein assay Sensorgram of WT and K246[A] binding to immobilized P5
on a streptavidin biosensor. The association of I-domain and P5 peptide occurs from
Time 0 to 360 seconds, which is followed by the dissociation of I-domain and P5 until
700 seconds.

As shown in Figure 17, the K246[A] mutant clearly demonstrates a significant reduction
in binding to P5 peptide compared to the Wild-Type I-domain. The shape of the binding
curve for Wild-Type I-domain is rectangular hyperbola and demonstrates moderate
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affinity for P5, while the K246[A] I-domain demonstrated a drastic reduction in binding.
Because binding was significantly diminished, we then tested the ability of the K246[A]
I-domain to bind to CEP using ForteBio Protein-Protein Assay. CEP was immobilized
onto an activated Amine Reactive ARG2 biosensor and I-domain binding to CEP was
measured in real time as shown below in Figure 18.

Figure 18. WT and Mutant K246[A] I-domain binding to CEP. Representative
ForteBio Octet Protein-Protein assay Sensorgram of WT and K246[A] binding to
immobilized CEP on an Amine-Reactive Arginine biosensor. The association of Idomain and CEP occurs from Time 0 to 500 seconds, which is followed by the
dissociation of I-domain and CEP until 1000 seconds.

K246[A] binding to CEP was tested with ForteBio 3 times, each assay clearly showing
that amino acid K246 is involved in binding to CEP as demonstrated by a significant
reduction in measured binding.
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Comparison of Wild-Type and Mutant I-domain Binding P5 Peptide
To compare the binding ability of all mutants to P5 peptide, the maximum
concentration of each mutant I-domain was converted to a percentage relative to the
Wild-Type I-domain binding tested in each assay. The comparison of all mutants reveals
that only mutant K246[A] demonstrated a significant, drastic reduction in ability to bind
to P5 peptide as shown in Figure 19 below.

Figure 19. Comparison of Mutant I-Domains Binding to P5 Peptide. Mutant Idomains binding to P5 as measured by ForteBio Protein-Protein Assay shown as a
percentage to Wild-Type. Wild-Type binding to P5 peptide was calculated as 100% and
is represented as the dotted line. N=2 for each mutant I-domain, excluding K180[A]
where N=4.
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aDb2-K246[A] Transfected HEK293 Cells Demonstrated a Significant Reduction in
Binding to CEP
As the K246[A] mutation greatly reduced the I-domain’s ability to bind P5 peptide
and CEP during the ForteBio assays, we decided to verify our finding using the entire
integrin aDb2 receptor expressed on the surface of HEK293 cells. The cells were tested
by adhesion assay to immobilized CEP and also to fibrinogen.
The K246[A] I-domain mutation was introduced into a construct containing the
entire integrin aD sequence, which was previously cloned in pcDNA3.1 (Neo) vector,
using PCR Site-Directed Mutagenesis as described in the Methods. HEK293 cells were
transfected with the integrin b2 construct (pcDNA3.1 (hygro) vector) and integrin aDK246[A] mutagenic construct using Lipofectamine 2000. Positive clones were selected
after 14 days incubation with 500 ug/ml G418 and 250ug/ml hygromycin. The cells with
similar surface density of wild-type aDb2 and K246[A] mutant were selected by Cell
sorting (Fig.21 A).
The ability of Wild-type and K246[A] mutant aDb2-tranfected HEK293 cells to bind
CEP was assessed by cell adhesion assay as described in the methods. Wild-type
aDb2-tranfected HEK293 cells served as the control. The Wild-Type and aDb2-K246[A]
transfected HEK293 cells adhesion to CEP is shown below in Figure 20 B,C.
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Figure 20. WT and K246 Mutant aDb2-Transfected HEK293 Cells Adhering to CEP.
Transfected HEK293 Cells containing the K246 mutation showed significant decrease in
adhesion to CEP compared to the Wild-Type. A. The level of integrin aD expression
evaluated by flow cytometry with anti-aD polyclonal antibody. B. Adhesion of WT and
K246 Mutant to CEP calculated as a percent to WT. Representative result from 4
performed experiments. Statistical analysis was calculated using Student’s t-test,
p<0.003. C. Microscopical image of WT and K246 mutant HEK 293 cell adherence to
CEP on plate. Magnification 100x.
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As described above in Figure 20, adhesion to CEP for transfected HEK293 cells
containing the K246[A] mutation was significantly reduced compared to the Wild-Type.
This finding indicates that amino acid K246 is likely involved in the integrin aDb2-CEP
interaction. Adhesion of Wild-Type and K246 mutant aDb2 cells to fibrinogen was also
tested, as fibrinogen is another known ligand of integrin aDb2.

Adhesion to fibrinogen
120

N/S

100
80
60
40
20

Adherent cells, % of control

0

WT

K246 mutant

Figure 21: WT and K246 Mutant aDb2-Transfected HEK293 Cells Adhering to
Fibrinogen. Transfected HEK293 Cells containing the K246 mutation showed no
significant difference in adhesion to fibrinogen compared to the Wild-Type. Statistical
analysis was performed using Student’s t-test.

As shown above in Figure 21, there was no significant difference in the ability of K246
Mutant aDb2-Transfected HEK293 to bind to fibrinogen compared to the Wild-type.
Importantly, this finding confirms that the K246 mutant integrin is stable and capable of
binding ligand in a manner similar to the Wild-Type aDb2 integrin – providing more
evidence that amino acid K246 is involved in binding to the P5 peptide and CEP.
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CHAPTER 4. DISCUSSION
Integrin aDb2 has been shown to promote macrophage retention and
accumulation within inflamed tissue, a key event in development of chronic
inflammation. The upregulation of integrin aDb2 on pro-inflammatory macrophages is
believed to function as a brake signal which prevents further migration after arrival at
the site of inflammation. However, during chronic inflammatory reactions this
macrophage accumulation and retention within inflamed tissue leads to host tissue
damage, formation of chronic inflammatory lesion, and eventually development of
chronic inflammatory disease.
Because of the unique upregulation of integrin aDb2 on inflammatory
macrophages, it is an attractive target to prevent chronic inflammation. After identifying
2-(ω-carboxyethyl) pyrole (CEP), an oxidative modification to proteins and
phospholipids found within inflamed tissue, as a ligand for integrin aDb2, a specific
inhibitor targeting the integrin aDb2-CEP interaction was created. The resulting 15 amino
acid peptide, called P5, successfully reduced macrophage retention and accumulation
within inflamed tissue both in vitro and in vivo. The purpose of this thesis was to identify
amino acids of human macrophage integrin aDb2 which participate in binding to P5
peptide and likewise to CEP.
As the P5 peptide carries a strong negative charge and does not bind to other
similar integrins by design, we hypothesized that basic amino acid residues of the aD
subunit I-domain which are not conserved among members of the b2 integrin family are
responsible for binding to P5. Through comparative analysis of sequences and
structures, 8 amino acids of the aD subunit I-domain were selected to create 6 mutant I-
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domains for analysis: K180[A], R189[Q], K205[L], HHK223-225[NIT], K233[A], and
K246[A].
Though the location and protruding positive charge generated by aD amino acid
K180 seemed to play a role in binding to P5, this amino acid is likely not involved in the
P5-aDb2 or CEP-aDb2 interaction as no difference in binding was observed compared to
the Wild-Type I-domain. As a basic residue is conserved in this position in the aM
subunit, R181, perhaps aD amino acid K180 participates in binding fibrinogen or other
ligands also recognized by the aM subunit.
Mutation of aD amino acid R189 lead to a slight decrease in binding to P5 peptide
as measured by ForteBio but overall there was not a significant difference as compared
to Wild-Type I-domain. As this amino acid is located in Pocket 1 of the aD subunit, the
slight decrease in binding could point to an important role in ligand binding for this
pocket. However, the other amino acids within this pocket which were analyzed,
HHK223-225[NIT] and K233[A], displayed a significant increase in binding. We
hypothesize that disruptions to Pocket 1 lead to a redistribution of surface charge which
exposes additional ligand binding sites and results in the observed increased in binding.
Interestingly, mutant K205[L] also demonstrated a significant increase in binding
to P5 compared to the Wild-Type I-domain as measured by ForteBio Protein-Protein
Assay. The potential explanation for this increase in binding is also related to changes
in the 3D conformation of the I-domain, leading to exposition of additional ligand binding
sites which are naturally unavailable. Nevertheless, these findings show that these
amino acids are not involved in binding to P5 peptide.
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Of the 6 mutant aD I-domains analyzed, only one mutant, K246[A], showed a
dramatic and significant reduction in ability to bind to both P5 peptide and CEP as
measured by ForteBio. Further, adhesion to CEP was also significantly reduced
compared to the Wild-Type when the K246[A] mutation was introduced into the entire
integrin aDb2 receptor and expressed on the surface of HEK293 cells. Adhesion to
fibrinogen for cells expressing the aDb2-K246[A] mutant showed no effect compared to
the Wild-Type, indicating that the mutant I-domain is conformationally stable and is not
critical for the binding to fibrinogen.
Despite several key functions in inflammation, pathogen response, and tissue
injury, much remains unknown about integrin aDb2. These findings are important
because they provide more detail into ligand recognition and binding for this
understudied integrin. Future directions include a continuation of this study focused on
identifying the other amino acids involved in the aDb2-CEP interaction, as this is the first
step in developing a major therapeutic antibody with potential to prevent chronic
inflammation. Antibody targeting aD amino acids which bind to CEP, including amino
acid K246 identified in this study, would prevent macrophage adherence within sites of
inflammation and effectively reduce macrophage accumulation and retention within
inflamed tissue, thus reducing or eliminating chronic inflammatory reactions. As chronic
inflammation affects millions of people around the globe, we hope these findings serve
as a stepping stone in the future development of a clinically relevant inhibitor of chronic
inflammation.
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